You won’t believe how fast the FDA just greenlit Eli Lilly’s new obesity pill, Foundayo — and the rival drama it’s already stirring. The once-daily tablet just became the second GLP-1 pill approved to treat obesity, instantly setting the stage for a glossy, high-stakes face-off with Novo Nordisk’s pill version of Wegovy.

Here’s the headline-grabber: the FDA moved at lightning speed, approving Foundayo in just 50 days under a fast-track pathway reserved for national priority treatments — reportedly the quickest greenlight for a brand-new type of drug since 2002. Patients now have a genuine choice of pills instead of injections from both makers of the category’s marquee medicines, a shift that could tempt the needle-averse and simplify daily routines.

Foundayo’s secret sauce is orforglipron, a small-molecule GLP-1–acting compound that is not a peptide like many injectables. Translation from lab-speak to salon gossip: it’s designed to be absorbed easily as a pill and can be taken any time of day without food or water rules. That convenience is a direct contrast to the Wegovy pill, which must be taken on an empty stomach with a brief fasting window — a detail that can trip up the best of intentions when life gets hectic.

Now, about the results everyone’s whispering about: in a Lilly trial reviewed by the FDA, patients on the highest dose of Foundayo over 72 weeks lost an average of 27.3 pounds — about 12.4% of their body weight — versus roughly 2.2 pounds, or 0.9%, on placebo. The most common side effects were the usual GLP-1 suspects like nausea, constipation, and diarrhea. That said, Novo Nordisk is not letting the narrative run away: the company is pushing back on any chatter that Foundayo outperforms Wegovy’s pill, noting there has been no head-to-head trial to prove superiority. Consider the gauntlet dropped, with receipts pending.

Of course, the glamour comes with a caveat: price tags and patchy insurance coverage remain the mood-killers. Even with more convenient pills on the market, access will hinge on what plans cover and what patients can afford. Still, the approval signals a new phase in the weight-loss arms race — with Foundayo playing convenience queen and Wegovy guarding its crown. Expect pharmacy counters, prescribers, and insurers to become the next runway where this rivalry struts.